oa HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack

References

1. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996; 124:Suppl:S11–S20.
   [Google Scholar]
2. Wilkins JT, Ning H, Stone NJ, Criqui MH, Zhao L, Lloyd-jones DM. Coronary heart disease risks associated with high levels of HDL cholesterol. J Am Hear Assoc. 2014; 3::e000519.
   [Google Scholar]
3. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008; 101:8A:20B–26B.
   [Google Scholar]
4. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators . Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357:21:2109–2122.
   [Google Scholar]
5. Schwartz G, Chaitman BBR, Holme IM, Kallend DD, Leiter LA, Leitersdorf E, Mcmurray JJV. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367::2089–2099.
   [Google Scholar]
6. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371:3:203–212.
   [Google Scholar]
7. AIM-HIGH Investigators , Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2012; 365:24:2255–2267.
   [Google Scholar]
8. Anderson TJ, Boden WE, Desvigne-Nickens P, Fleg JL, Kashyap ML, McBride R, Probstfield JL, AIM-HIGH Investigators . Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med. 2014; 371:3:288–290.
   [Google Scholar]
9. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:15:1495–1504.
   [Google Scholar]
10. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004; 93:2:154–158.
    [Google Scholar]
11. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975; 231::360–381.
    [Google Scholar]
12. HPS2-THRIVE Collaborative Group , Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371:3:203–212.
    [Google Scholar]
13. Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ, Joshi PH, Toth PP, Muhlestein JB, Anderson JL, Knight S, Li Y, Spertus JA, Jones SR, on behalf of the Lipoprotein Investigators Collaborative (LIC) . HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. Eur Heart J. 2014;, pii: ehu264. http://dx.doi.org/10.1093/eurheartj/ ehu264 .
    [Google Scholar]
14. Rosenson RS, Bryan Brewer H Jr, Sean D, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang X-C, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Contemporary reviews in cardiovascular medicine: Cholesterol efflux and atheroprotection. Circulation. 2012; 125::1905–1919.
    [Google Scholar]
15. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med. 1999; 341::410–418.
    [Google Scholar]
16. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice Guidelines . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014; 63::2889–2934.
    [Google Scholar]
17. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute , Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, Lu Y, Tang ZZ, Zhang H, Hindy G, Masca N, Stirrups K, Kanoni S, Do R, Jun G, Hu Y, Kang HM, Xue C, Goel A, Farrall M, Duga S, Merlini PA, Asselta R, Girelli D, Olivieri O, Martinelli N, Yin W, Reilly D, Speliotes E, Fox CS, Hveem K, Holmen OL, Nikpay M, Farlow DN, Assimes TL, Franceschini N, Robinson J, North KE, Martin LW, DePristo M, Gupta N, Escher SA, Jansson JH, Van Zuydam N, Palmer CN, Wareham N, Koch W, Meitinger T, Peters A, Lieb W, Erbel R, Konig IR, Kruppa J, Degenhardt F, Gottesman O, Bottinger EP, O'Donnell CJ, Psaty BM, Ballantyne CM, Abecasis G, Ordovas JM, Melander O, Watkins H, Orho-Melander M, Ardissino D, Loos RJ, McPherson R, Willer CJ, Erdmann J, Hall AS, Samani NJ, Deloukas P, Schunkert H, Wilson JG, Kooperberg C, Rich SS, Tracy RP, Lin DY, Altshuler D, Gabriel S, Nickerson DA, Jarvik GP, Cupples LA, Reiner AP, Boerwinkle E, Kathiresan S. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014; 371:22–31.
    [Google Scholar]